Phase 3 clinical results of GSK/Medicago new crown plant-derived adjuvant vaccine candidate announced

GlaxoSmithKline (GSK) and Medicago recently announced that the COVID-19 plant-derived vaccine candidate added with GSK pandemic adjuvant has achieved positive results in its efficacy and safety in the global phase 3 placebo-controlled efficacy study

The vaccine's efficacy has been proven in an environment dominated by SARS-CoV-2 variants, which is different from most of the published Phase 3 trials

During the study period, no related serious adverse events were reported, and the reactogenicity was generally mild to moderate and transient; the symptoms lasted only one to three days on average

Based on these results, Medicago will immediately seek registration approval from Health Canada as part of its rolling application

Medicago has initiated the registration and application procedures for plant-derived adjuvant new coronary pneumonia vaccine candidates in the US FDA and UK MHRA

Note: The original text has been deleted